On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading
On November 1, 2024, Knowledge Ecology International (KEI) submitted a proposal for the addition of risdiplam to the World Health Organization’s (WHO) Model List of Essential Medicine (EML). You can access the full proposal here: risdiplam2WHOEML1Nov2024 The EML, updated every… Continue Reading
Comment on proposal by several countries to add language clarifying references to MAT or VMAT on the transfer of technology or know-how is without prejudice to other measures KEI Briefing Note 2024:2A James Love Knowledge Ecology International (KEI) May 21,… Continue Reading
On October 3, 2023, Knowledge Ecology International (KEI) sent a letter to the FDA asking the agency to publish its historical Orange Book data. The Orange Book identifies patent and exclusivity data for FDA approved drug products. The FDA publicly… Continue Reading
On Thursday, 12 September 2024, non-State actors in official relations and relevant stakeholders were invited to join a “brief open session at the beginning of the day.” In advance of Thursday’s discussions on Article 13 (Supply chain and logistics) and… Continue Reading
On Monday afternoon, 9 September 2024, Knowledge Ecology International (KEI) delivered this statement on the complementarity and coherence between the amended International Health Regulations (2005), adopted by the Seventy‑seventh World Health Assembly, and the proposal for the WHO Pandemic Agreement… Continue Reading
On Monday afternoon, 9 September 2024, Knowledge Ecology International (KEI) delivered this statement on the legal architecture of the proposal for the WHO Pandemic Agreement. KEI has an open mind regarding the appropriate nature of the instrument or instruments for… Continue Reading
On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading
The PDF version of the letter has all tables and footnotes: KEI-NIH-28Aug2028 August 28, 2024 Abby Rives, JD Division Director Technology Transfer and Innovation Policy National Institutes for Health Vladimir Knezevic, MD Senior Advisor for Commercial Evaluation Technology Advancement Office… Continue Reading
In advance of the September 2024 WHO pandemic negotiations (INB 11), Knowledge Ecology International (KEI), Innovarte, and Medicines Law & Policy (ML&P) will convene a virtual panel entitled, “Reflections on the IP & Technology Transfer provisions of the WHO Pandemic… Continue Reading